These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27836486)

  • 21. Positive immunoreactivity for vesicular monoamine transporter 2 in Lewy bodies and Lewy neurites in substantia nigra.
    Yamamoto S; Fukae J; Mori H; Mizuno Y; Hattori N
    Neurosci Lett; 2006 Apr; 396(3):187-91. PubMed ID: 16386370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degeneration.
    Alter SP; Stout KA; Lohr KM; Taylor TN; Shepherd KR; Wang M; Guillot TS; Miller GW
    Exp Neurol; 2016 Jan; 275 Pt 1(Pt 1):17-24. PubMed ID: 26428905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vesicular monoamine transporter, type 2 (VMAT2) expression as it compares to insulin and pancreatic polypeptide in the head, body and tail of the human pancreas.
    Freeby M; Ichise M; Harris PE
    Islets; 2012; 4(6):393-7. PubMed ID: 23221614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons.
    Guillot TS; Miller GW
    Mol Neurobiol; 2009 Apr; 39(2):149-70. PubMed ID: 19259829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of the substrate binding region of vesicular monoamine transporter-2 (VMAT-2) using iodoaminoflisopolol as a novel photoprobe.
    Gopalakrishnan A; Sievert M; Ruoho AE
    Mol Pharmacol; 2007 Dec; 72(6):1567-75. PubMed ID: 17766642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distribution of vesicular monoamine transporter 2 protein in human brain: implications for brain imaging studies.
    Tong J; Boileau I; Furukawa Y; Chang LJ; Wilson AA; Houle S; Kish SJ
    J Cereb Blood Flow Metab; 2011 Oct; 31(10):2065-75. PubMed ID: 21522164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. VMAT2 and Parkinson's disease: harnessing the dopamine vesicle.
    Lohr KM; Miller GW
    Expert Rev Neurother; 2014 Oct; 14(10):1115-7. PubMed ID: 25220836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vesicular monoamine and glutamate transporters select distinct synaptic vesicle recycling pathways.
    Onoa B; Li H; Gagnon-Bartsch JA; Elias LA; Edwards RH
    J Neurosci; 2010 Jun; 30(23):7917-27. PubMed ID: 20534840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mitochondrial complex I inhibitor rotenone inhibits and redistributes vesicular monoamine transporter 2 via nitration in human dopaminergic SH-SY5Y cells.
    Watabe M; Nakaki T
    Mol Pharmacol; 2008 Oct; 74(4):933-40. PubMed ID: 18599602
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: human midbrain dopamine neurons.
    Liang CL; Nelson O; Yazdani U; Pasbakhsh P; German DC
    J Comp Neurol; 2004 May; 473(1):97-106. PubMed ID: 15067721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The vesicular monoamine transporter 2: an underexplored pharmacological target.
    Bernstein AI; Stout KA; Miller GW
    Neurochem Int; 2014 Jul; 73():89-97. PubMed ID: 24398404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Region-specific targeting of dopamine D2-receptors and somatodendritic vesicular monoamine transporter 2 (VMAT2) within ventral tegmental area subdivisions.
    Pickel VM; Chan J; Nirenberg MJ
    Synapse; 2002 Aug; 45(2):113-24. PubMed ID: 12112404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Severe serotonin depletion after conditional deletion of the vesicular monoamine transporter 2 gene in serotonin neurons: neural and behavioral consequences.
    Narboux-Nême N; Sagné C; Doly S; Diaz SL; Martin CB; Angenard G; Martres MP; Giros B; Hamon M; Lanfumey L; Gaspar P; Mongeau R
    Neuropsychopharmacology; 2011 Nov; 36(12):2538-50. PubMed ID: 21814181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New fluorescent substrate enables quantitative and high-throughput examination of vesicular monoamine transporter 2 (VMAT2).
    Hu G; Henke A; Karpowicz RJ; Sonders MS; Farrimond F; Edwards R; Sulzer D; Sames D
    ACS Chem Biol; 2013 Sep; 8(9):1947-54. PubMed ID: 23859623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The molecular chaperone Hsc70 interacts with the vesicular monoamine transporter-2.
    Requena DF; Parra LA; Baust TB; Quiroz M; Leak RK; Garcia-Olivares J; Torres GE
    J Neurochem; 2009 Jul; 110(2):581-94. PubMed ID: 19457116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters.
    Kung MP; Hou C; Goswami R; Ponde DE; Kilbourn MR; Kung HF
    Nucl Med Biol; 2007 Apr; 34(3):239-46. PubMed ID: 17383573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A metabolomic study of brain tissues from aged mice with low expression of the vesicular monoamine transporter 2 (VMAT2) gene.
    Salek RM; Colebrooke RE; Macintosh R; Lynch PJ; Sweatman BC; Emson PC; Griffin JL
    Neurochem Res; 2008 Feb; 33(2):292-300. PubMed ID: 18041582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. C1 neurons in the rat rostral ventrolateral medulla differentially express vesicular monoamine transporter 2 in soma and axonal compartments.
    Sevigny CP; Bassi J; Teschemacher AG; Kim KS; Williams DA; Anderson CR; Allen AM
    Eur J Neurosci; 2008 Oct; 28(8):1536-44. PubMed ID: 18973576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
    Kilbourn MR; Kuszpit K; Sherman P
    Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
    Provencher BA; Eshleman AJ; Johnson RA; Shi X; Kryatova O; Nelson J; Tian J; Gonzalez M; Meltzer PC; Janowsky A
    J Med Chem; 2018 Oct; 61(20):9121-9131. PubMed ID: 30240563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.